Background
==========

Ovarian ageing, as manifested by reduced ovarian reserve, is responsible for the well-established observation of age related decline in fertility \[[@B1],[@B2]\] and of age related increase in adverse reproductive events such as miscarriages \[[@B3]\] and aneuploid pregnancies \[[@B4]\]. While ovarian ageing is one of the major determinants of outcome following in-vitro fertilization (IVF), women with reduced ovarian reserve often respond poorly to controlled ovarian stimulation resulting in retrieval of fewer oocytes, producing poorer quality embryos and reduced implantation rates and pregnancy rates. Incidence of poor ovarian response, a measure of reduced ovarian reserve, ranges from 9-24% in the earlier report \[[@B5]\] but is increasing \[[@B6]\] because of global rise in the number of women who defer conceiving to their 30s or 40s. Various treatment regimens including different stimulation protocols and adjuvant therapies have been reported to improve ovarian response and pregnancy rates in women with diminished ovarian reserve but none of them have been proven to be superior over the others to recommend any one of them as the best protocol of choice \[[@B7]\].

It has been proposed that oral administration of Dehydroepiandrosterone (DHEA), an adrenal androgen, may have anti-ageing effects and may improve ovarian response and pregnancy rates in women with reduced ovarian reserve during IVF. Casson et al., in the year 2000, who had interest in the use of DHEA for hormone replacement therapy (HRT) were the first group that reported the benefits of DHEA supplementation for improving the response to ovarian stimulation in a case series \[[@B8]\]. Since then, a few controlled studies including a randomised controlled study, but with small sample sizes, have subsequently reported benefits of DHEA supplementation to improve ovarian response and IVF outcome \[[@B9]\]. While the mechanism of action for this improved IVF outcome following DHEA administration remains speculative, controlled studies have demonstrated oral DHEA supplementation increases serum IGF-I concentrations, which are known to have a positive effect on follicular development and oocyte quality. Further, it is well established that androgens can directly influence ovarian follicle development by local intra-ovarian androgen receptor mediated actions \[[@B10],[@B11]\] and it is therefore possible that DHEA may enhance the follicular environment through: augmentation of the growth promoting and survival enhancing effect of IGF-I; LH-stimulated follicular androgen and oestrogen production \[[@B12]\]; and the augmentation of granulosa cell FSH-receptor (FSH-r) expression and associated increase in the number of growing preantral and small antral follicles \[[@B13],[@B14]\]. In addition, given the published report of DHEA on reducing miscarriage rates in older patients, a direct- or indirect- effect of DHEA at the level of the oocyte cannot be ruled out. DHEA could potentially improve oocyte quality via the GH axis through the promotion of DNA repair in oocytes \[[@B15]\]. An effect of DHEA on mitochondrial activity in both follicular cells and oocytes is also possible since androgens have been shown to beneficially affect mitochondrial function \[[@B16]\].

A recent world-wide survey has shown that over a quarter (26%) of IVF clinicians add DHEA as an adjuvant to IVF treatment protocols in women with poor ovarian response \[[@B6]\]. Despite widespread use of DHEA, clinical evidence as well as knowledge regarding underlying mechanisms of DHEA on improvement of ovarian response is still limited. A recent systematic review by Sunkara et al. investigating the role of androgens (testosterone, DHEA, and aromatase inhibitor- Letrozole) in poor-responders undergoing IVF treatment could not show significantly improvement in terms of pregnancy rates and other parameters such as number of oocytes retrieved \[[@B17]\]. While Sunkara et al.'s review included all the androgen adjuvants, there is no systematic review and meta-analysis reported specifically on the role of DHEA alone in women with diminished ovarian reserve. This systematic review aims to summarize the role of DHEA as an adjuvant to stimulation protocol in women with diminished ovarian reserve or poor-responders based on meta-analysis of the published controlled studies.

Methods
=======

We searched EMBASE (1980 to December 2012), MEDLINE (1948 to December 2012), Pubmed and Cochrane Library for all relevant articles under the following Medical Subject Headings (MeSH) terms to generate subsets of studies; i) 'DHEA' or Dehydroepiandrosterone', ii) 'Poor response' or 'low response', and iii) 'Diminished ovarian reserve' or 'Premature ovarian aging'. Combining these subsets together (subset i with either ii or iii) by 'AND' to identify citations appropriate to the question 'The effect of DHEA supplementation on ovarian stimulation outcomes in diminished ovarian reserve and/or poor responses patients'. The search also tracked on ISI conference abstracts as well as on-going randomised controlled trials registered on ISRCTN database. In addition, all primary papers' bibliographies were explored to recognize cited publications which had not been identified by electronic-based searches. Only articles written in English were included in the meta-analysis. The searches were conducted by two reviewers independently (AN and KJ).

The target population was either poor-responders or those with diminished ovarian reserve, as described above, who were undergoing ovarian stimulation plus IVF/ICSI. DHEA was supplemented before ovarian stimulation in the study group while neither was used in the control. The primary outcome was the clinical pregnancy rate and the secondary outcomes were oocyte yield (numbers of oocytes retrieved), miscarriage rate, live birth rate and aneuploidy rates.

All full manuscripts were reviewed for the selection and exclusion of publications with predefined inclusion criteria by two reviewers (AN and KJ) independently. Extraction data for each study, e.g. study design, inclusion/exclusion criteria, population characteristics, definition of diminished ovarian reserve, stimulation protocol, and outcomes, was separately done by two of the authors (AN and KJ) using pre-determined tables and form. Disagreements about either article selection or data extraction were resolved by consensus or arbitration by a third reviewer (BKC). The Newcastle-Ottawa Scale (NOS) scoring system \[[@B18]\] was used to assess methodology and quality of observational studies (non-randomised trials). For RCT, the full publication was scrutinized to identify study characteristics; randomisation, allocation, blinding, and intention-to-treat analysis.

Statistical analysis
--------------------

Relative risks (RR) from individual studies were analysed using random effects models \[[@B19]\]. Heterogeneity of exposure effects was evaluated graphically using forest plots (Lewis and Clarke, 2001) and statistically using the I^2^ statistic to quantify heterogeneity across studies \[[@B20]\]. Statistical analyses were performed using RevMan 5.1 software (Cochrane Collaboration, Oxford, UK).

Results
=======

The search yielded 38 publications of which 16 excluded by screening through titles and abstracts, including one paper that is not published in English. Full manuscripts were retrieved for the remaining 22 articles, which included 3 case series \[[@B21]-[@B23]\], 3 case-control \[[@B24]-[@B26]\], 7 prospective self-controlled studies \[[@B8],[@B12],[@B27]-[@B31]\], 1 randomised controlled trial (RCT) \[[@B9]\], 3 abstract oral/poster presentations \[[@B32]-[@B34]\], and 5 reviews \[[@B22],[@B35]-[@B38]\]. Studies that have matched controls were identified eligible for analyses. Study characteristics of controlled studies are presented in Table [1](#T1){ref-type="table"} whereas quality of all studies included in the meta-analysis is shown in Table [2](#T2){ref-type="table"}.

###### 

Study characteristics of controlled studies (both RCT and non-RCTs) of DHEA supplementation in poor-responders or diminished ovarian reserve

  **Articles**                **Study design**      **Inclusion criteria**                                                                                                                                                                           **Cases/ Controls**                                          **Intervention (DHEA doses and duration)**                                          **Stimulation protocol**                                                            **Embryo transfer**                                              **Outcomes**                                                                                                                                                                    **Notes**
  --------------------------- --------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------ ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Barad D, et al. (2007)      Case--control         **POA** defined by age-specific baseline FSH levels \> 95% CI of mean value for the age group; but \< 12 mIU/ml **DOR** defined as baseline FSH \> 12 mIU/ml and/or estradiol level ≥ 75 pg/ml   89 cases\* and 101 controls \*only 64 of 89 undergoing IVF   Cases : DHEA 25 mg three times daily for mean duration 73 days continuously until   -Allow cases to conceive naturally; the other entered IVF using microdose agonist   Day 3 embryo transfer                                            -Clinical pregnancy rate -No. of retrieved oocytes -Implantation rate -Miscarriage rate -Normal day 3 embryos -Time from initial visit to pregnancy (Cox regression analysis)   -Cases were slightly older (P \< 0.05) -Fertility treatments were different (P \< 0.001) -Women in control entered IVF cycle more rapidly
                                                    positive pregnancy test                                                                                                                                                                          flare followed by high dose FSH + HMG (300--450 + 150 IU)                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                    Control : None                                                                                                                                                                                   -Similar protocol for both cases/controls                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Wiser A, et al. (2010)      RCT (open- labeled)   Age ≤ 41 yr, Poor response, previous IVF cycle with high dose Gn (FSH 300 IU) with oocyte \<5 or cycle cancellation                                                                              17 Cases                                                     Cases : DHEA 75 mg/day orally ≥ 6 weeks before stimulation                          \- Similar protocol for both cases/controls                                         Day 2--3 embryo transfer                                         -Peak estradiol levels                                                                                                                                                          Counted 55 IVF from 33 patients (both arms went through
                              16 Controls           Control : None                                                                                                                                                                                   \- Standard long GnRH agonist protocol                       Up to 3 embryos                                                                     -No. of retrieved oocytes                                                           Including of repeat cycles without adjustment of randomisation                                                                                                                                                                                   
                                                                                                                                                                                                                                                     \- Using rFSH 450 IU + rLH 150 IU                                                                                                                -Embryo quality and No. of reserve embryo                                                                                                                                                                                                                                                                                            
  Gleicher N, et al. (2010)   Case--control         DOR defined by abnormally age specific hormone levels deviated from 95% CI; elevated FSH or low AMH                                                                                              22 Cases                                                     Cases : DHEA 25 mg three times daily At least 4 weeks before stimulation            Microdose agonist flare followed by high dose FSH + HMG (300--450 + 150 IU)         Not being stated                                                 -Pregnancy and live birth rates (secondary outcome)                                                                                                                             Clinical pregnancy rate, miscarriage and No. of oocyte retrieved (our outcomes) are not the main outcome of the study.
                                                                                                                                                                                                                                                     44 matched Controls (1st single IVF cycle analysis only)                                                                                         -Similar protocol for both cases/controls                                           Pregnancy was not outcome of interest                            -Aneuploidy rate                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                  Control : None                                                                                                                                                                                                                           -No. of oocytes retrieved                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           -Total gonadotropin dosage                                                                                                                                                       

\*POA: Premature Ovarian Aging, DOR: Diminished Ovarian Reserve.

###### 

**Quality of controlled studies passing eligibility criteria presented by stratification of research methodology and Newcastle-Ottawa scale**^**a**^**(for non-randomised observational studies)**

  **Author/Year**             **Design**                    **Randomisation**                              **Blinding**   **Sample size estimation**   **Analysis**                   **Newcastle-Ottawa scale**       
  --------------------------- ----------------------------- ---------------------------------------------- -------------- ---------------------------- ----------------------------- ---------------------------- ---- --------
  Barad D, et al. (2007)      Case -control study           None                                           None           N/A                          Intention to treat analysis              \*\*\*             \*    \*\*
  Wiser A, et al. (2010)      Randomised controlled study   -Computer generated random numbers             None           Not done                     Intention to treat analysis                                         
                                                            \- allocation concealment by sealed envelope                                               (No-drop out)                                                       
  Gleicher N, et al. (2010)   Case -control study           None                                           None           N/A                          Intention to treat analysis              \*\*\*             \*   \*\*\*

^a^ Wells GA et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analysis, available from: URL: <http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp> \[cited 2012 June 1\].

Primary outcome: clinical pregnancy rate
----------------------------------------

Only two studies, one RCT \[[@B9]\] and one non-RCT \[[@B25]\], were selected for meta-analysis for the clinical pregnancy rate (CPR) outcome. Due to the fact that Wiser's study reported cumulative pregnancy outcome over two consecutive IVF cycles, only first cycle data was taken into account. Pooling data together (Figure [1](#F1){ref-type="fig"}A), there was no significant difference in the clinical pregnancy rate between women pre-treated with DHEA compared to those without DHEA pre-treatment (RR 1.87, 95% CI 0.96, 3.64; P=0.07). While there was homogeneity observed between the two included studies (I^2^\< 1%), the study designs were completely different as one was a case control study and the other, a randomised controlled trial.

![**Meta-analysis of clinical pregnancy and miscarriage rates.** Meta-analysis of studies of DHEA supplementation versus controls for outcome of **A**) clinical pregnancy rates and **B**) Miscarriage rates in DOR or poor responders undergoing IVF cycle.](1477-7827-11-44-1){#F1}

Secondary outcome: miscarriage rate
-----------------------------------

Similar to primary outcome, only two published controlled studies were eligible for analysis \[[@B9],[@B25]\]. The results from these studies showed that there was no difference between the DHEA and control groups (RR 0.59, 95% CI 0.21, 1.65; Figure [1](#F1){ref-type="fig"}B).

Further literature review revealed one particularly retrospective study from Gleicher et al. (2009) which specifically examines miscarriage rates. In this study, they reported that DHEA supplemented pregnancies in women with diminished ovarian reserve had lower miscarriage rates when compared to the national United States IVF database (OR 0.49; P=0.04) \[[@B26]\]. Because of lack of comparability between cases and controls, who did have diminished ovarian reserve and who did not, this study was therefore, excluded from meta-analysis.

Oocytes retrieved
-----------------

Regarding number of oocytes, meta-analysis of the three studies, one RCT \[[@B9]\] and two non-RCT \[[@B24],[@B25]\], demonstrated a significantly lower number of oocytes retrieved in DHEA treated women when compared to the controls (WMD -1.88, 95% CI -2.08, -1.67). However, a significant heterogeneity of 74% (I^2^) among studies was observed (Figure [2](#F2){ref-type="fig"}).

![**Meta-analysis of numbers of oocytes.** Meta-analysis of studies of DHEA supplementation versus controls for outcome of numbers of oocytes retrieved in DOR or Poor responders undergoing IVF cycle.](1477-7827-11-44-2){#F2}

Discussion
==========

This systematic review of the controlled studies that reported the effect of pre-treatment DHEA on IVF outcome in women with diminished ovarian reserve suggests that DHEA does not improve the quantitative ovarian response and pregnancy outcome. While the ovarian response as defined by the number of oocytes retrieved was significantly lower, the clinical pregnancy rate was marginally superior with a relative risk of 1.87 (95% CI 0.96-3.64; P=0.07) in the DHEA group. The miscarriage rate was similar between the DHEA and control groups on meta-analysis of the two reported controlled studies. This finding, however, is based on few data as there was only one study \[[@B9]\] which reported live birth rate, which was similar between the DHEA and control groups when only one cycle per participant was considered for analysis.

While there are several self-controlled case series on reported significant benefits in terms of ovarian response and pregnancy rates with the use of pre-treatment DHEA adjuvant during IVF, this systematic review of controlled studies failed to demonstrate such a benefit. However, while noting the trend of a positive effect of DHEA on the pregnancy rate in this review, the lack of a significant difference may be because of a small sample size with the overall number of participants that are included in the meta-analysis is only 198. In the study of Barad et al. 2007 included in this review, the authors have also reported spontaneous pregnancy (n=6/16) and pregnancy following IUI (6/9), which occurred during the three to four months waiting time of pre-IVF DHEA adjuvant treatment \[[@B25]\]. When these data were included in the meta-analysis, there was a significantly increased pregnancy rates in the DHEA arm over the controls (RR 2.46 95% CI 1.35, 4.48; P=0.003). Since our objective was to investigate the effect of DHEA in IVF cycle, we have included only the IVF population in the primary analysis.

At present, there is only a single small randomised controlled trial by Wiser et al. 2010 reported in literature \[[@B9]\]. The small sample size in this study resulted in only a minimal effect toward the result of the meta-analysis (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}). Furthermore, many limitations and weaknesses of Wiser's study have been criticised. First, there was no priori sample size estimation in the study. The authors included two cycles with varying duration of DHEA adjuvant treatment (7 -- 18 weeks) and the authors continued the trial until a significant difference in cumulative live birth rate between the study and control groups was achieved. There was no difference in the live birth rate between the study and control groups following their first cycle of IVF with the mean duration of DHEA therapy in the study group was for only about 8.5 weeks. Secondly, both patients and health care providers were not blinded in this study therefore bias could occur, or patients in the control group might have sought over-the-counter medication for themselves. And finally, one letter to the editor expressed concern over the statistical analysis in this study suggesting that because the author had included two consecutive IVF cycle data from each group, Kaplan-Meier survival analysis should have been used rather than Fisher's exact test, which was originally reported \[[@B39]\].

Most data on the favourable effect of DHEA adjuvant supplementation currently come from the study group led by Barad and Gleicher at the Centre of Human Reproduction, New York. They have published a series of self-controlled studies and retrospective case control analyses in which the benefits of DHEA are summarized as follows; i) increased oocyte yield \[[@B12]\] ii) higher fertilization rate \[[@B12]\] iii) improved embryo morphological grading \[[@B12]\] iv) increased pregnancy rate \[[@B25]\], v) lower miscarriage rate when compared to the national IVF statistics \[[@B26]\], and vi) lower aneuploidy rate \[[@B24]\]. We have included two of their suitable controlled studies in our meta-analysis (Table [1](#T1){ref-type="table"}). The authors also suggested that the benefit of DHEA treatment would be most effective if it is supplemented for at least 3-4 months, which is equal to the time needed for the early growing follicles to reach the gonadotropin-responsive stage \[[@B35]\]. Therefore, they believed that DHEA acts in both ovarian recruitment and early folliculogenesis. If this hypothesis is true, the duration of DHEA treatment is possibly a key factor in effecting a favourable change in ovarian response and pregnancy rates following IVF.

The data from the self-controlled studies should be interpreted with caution because of potential bias. In one review by Urman and Yakin, the authors retrospectively analysed IVF outcome in the second cycle of 801 patients who have history of poor ovarian response (production of ≤ 4 oocytes) in the first IVF cycle treatment in their centre. It was found that almost 40% of this cohort developed better response yielding more than 4 oocytes in their next cycle \[[@B37]\]. These data also confirm that poor response cannot be predicted only by history. Using other predictive tools to determine ovarian reserve, for instance antral follicle count or serum AMH, or both, is also critical to identify patients who will mostly benefits from DHEA in the clinical trial \[[@B40]\].

This systematic review did not include any self controlled studies, but included only the studies that had a group of contemporaneous controls. Our results in this review indicate that DHEA decreases the ovarian response as indicated by reduced number of oocytes retrieved at egg collection in the study arm. While this finding is surprising and it is difficult to come up with a scientific explanation, this systematic review is limited by a small number of treatment cycles included in the meta-analysis and by the heterogeneity of the included studies. On the contrary to the above finding, as indicated by trends of improving clinical pregnancy and of reducing miscarriage albeit no statistical significance, DHEA may have a positive effect on improving oocyte and embryo quality. It is already established that poor oocyte quality, which leads to producing poorer quality embryos, represents one of the clinical presentations of ovarian ageing \[[@B41]\]. The finding of potential effects of DHEA on oocyte quality and ovarian response warrant well-designed randomised controlled clinical trials of an adequate sample size using well-defined uniform inclusion criteria before recommending the use of DHEA in standard assisted reproduction treatment. In addition, further in-vivo and in-vitro embryological and endocrinological research to elucidate the mechanism of action of DHEA on ovarian folliculogenesis and on oocyte/embryo quality are also required.

Recent meta-analysis which evaluated the effect of adjuvant androgens (DHEA or Testosterone) or androgen-modulating agents (Letrozole, aromatase inhibitor) in previous poor responders has failed to demonstrate any significant difference in the ongoing pregnancy rate, live birth rates, and numbers of oocytes retrieved when compared with the control group, who have had no adjuvant therapy \[[@B17]\]. Another systematic review by Bosdou et al. 2012 reports a significant increase in clinical pregnancy and live birth rates in poor responder women who are pre-treated with transdermal testosterone, but not in other androgen modulating agents including DHEA, when compared to controls \[[@B42]\]. The review by Bosdou et al. on DHEA included only one study with a small sample size (n=33) in contrast to this review in which we included two other eligible controlled studies with larger sample sizes. However, it is important to note that all the reviews including ours are still limited by small sample sizes and heterogeneity between the studies included. In addition, there is a wide methodological variation in different studies in terms of different preparations that are used as adjuvants, and duration and timing, in relation to down regulation and ovarian stimulation during IVF, of adjuvant treatments. This conflicting data regarding the use of androgen and androgen modulating agents require further investigation by well-designed randomised controlled trials.

Conclusions
===========

In conclusion, our systematic review of the controlled studies on the effect of pre-treatment DHEA on IVF outcome in women with diminished ovarian reserve suggests that DHEA does not improve the quantitative ovarian response and pregnancy outcome. Based on these data, DHEA adjuvant therapy cannot be recommended in diminished ovarian reserve for improving IVF outcome. However, as the sample size in this analysis was small and the effect of DHEA on pregnancy rates approached close to statistical significance, further large scale multicentre randomised controlled studies are required to clarify the benefits of DHEA adjuvant therapy in routine clinical management of predicted poor responders.
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